Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone - A cross-over study in healthy volunteers

被引:172
作者
Leach, CL
Davidson, PJ
Hasselquist, BE
Boudreau, RJ
机构
[1] 3M Pharmaceut, St Paul, MN USA
[2] Univ Minnesota, Dept Radiol, Minneapolis, MN 55455 USA
关键词
belcomethasone dipropionate; chlorofluorocarbon-free propellant; fluticasone propionate; hydrofluoroalkane; lung deposition; Tc-99m aerosol;
D O I
10.1378/chest.122.2.510
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Study objectives: To compare the lung deposition of radiolabeled hydrofluoralkane-134a beclomethasone dipropionate (HFA-BDP) with chlorofluorocarbon fluticasone propionate (CFC-FP) and chlorofluorocarbon beclomethasone (CFC-BDP). Design: Six-day, open-label, nonrandomized, crossover study. Setting: Clinical research laboratory. Participants: Nine healthy, nonsmoking, adult volunteers. Interventions: On each study day, participants inhaled one or two puffs of Tc-99m-labeled HFA-BDP, CFC-FP, or CFC-BDP. All products delivered 50 mug per puff ex-valve. Subjects used a respiratory training and monitoring device to meet predefined, standardized inhalation patterns. Immediately after inhalation of radiolabeled study, drug, planar gamma camera images were obtained. Measurements and results: Radiolabeled HFA-BDP had a higher deposition in the lungs (53% ex-actuator) compared with CFC-FP (12 to 13%) and CFC-BDP (4%). Conversely, CFC-FP and CFC-BDP had a much higher distribution to the oropharynx (72 to 78%, and 82%, respectively) than HFA-BDP (29%). HFA-BDP was deposited evenly throughout the lungs, while CFC-FP and CFC-BDP deposition was primarily in the large central and intermediate airways. Andersen particle size sampling gave mass median aerodynamic diameters for HFA-BDP, CFC-FP,and CFC-BDP of 1 0.9 mum, 2.0 mum, and 3.5 mum, respectively. Conclusions: Lung deposition was greater with HFA-BDP compared with CFC-FP and CFC-BDP. Deposition values appeared to be related to the particle size distribution of each inhaler, with the smaller particles of HFA-BDP providing the greatest lung deposition and least oropharyngeal 1 deposition.
引用
收藏
页码:510 / 516
页数:7
相关论文
共 28 条
[21]  
Leach CL, 1998, J AEROSOL MED, V11, pS29
[22]   Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone [J].
Leach, CL ;
Davidson, PJ ;
Boudreau, RJ .
EUROPEAN RESPIRATORY JOURNAL, 1998, 12 (06) :1346-1353
[23]  
MAGNUSSEN H, 2000, RES MED, V94, P561
[24]  
National Heart Lung and Blood Institute, 1995, NIH PUBL
[25]  
Rahman S, 2000, AM J RESP CRIT CARE, V161, pA177
[26]   Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects [J].
Thorsson, L ;
Dahlstrom, K ;
Edsbacker, S ;
Kallen, A ;
Paulson, J ;
Wiren, JE .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 43 (02) :155-161
[27]   Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma [J].
Vanden Burgt, JA ;
Busse, WW ;
Martin, RJ ;
Szefler, SJ ;
Donnell, D .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2000, 106 (06) :1210-1226
[28]   Differences in lung bioavailability between different propellants for fluticasone propionate [J].
Wilson, AM ;
Sims, EJ ;
Orr, LC ;
Lipworth, BJ .
LANCET, 1999, 354 (9187) :1357-1358